Compare Crispr Therapeutics AG (CRSP) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Marsh & McLennan Companies, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 17.3× Crispr Therapeutics AG's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| CRSP | MRSH | |
|---|---|---|
Market Cap | $4.88B | $84.31B |
Volume | 2,861,747 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $74.92 | $207.02 |
52-Week Low | $44.34 | $157.32 |
Typical Hold Time | 77 Days | 109 Days |
Enterprise Value | $3.30B | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
MRSH trades at $176.16, up 1.44% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company completed the acquisition of Accel Holdings on October 2, 2026, expanding its advisory footprint. Revenue grew to $27.0B in 2025, with a net income margin of 15.41%, while valuation ratios like P/E of 21.57 and ROE of 25.72% reflect strong profitability. Analysts maintain a consensus price target of $202.71, though sentiment is mixed with a 'Hold' rating from most.
The outlook for MRSH is positive due to earnings momentum and strategic acquisitions, but risks include competitive pressures and potential margin compression. Upside remains if the company meets Q3 2026 EPS expectations of $1.97, supported by solid cash flow trends. Investors should weigh the high P/B ratio of 5.55 against growth prospects in the reinsurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
